皮疹和内分泌疾病预测了免疫疗法治疗的转移性细胞癌的改善生存率
Koichi Sugimoto1, Takafumi Minami1, Shingo Toyoda1
1Department of Urology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Anticancer research
|August 1, 2025
概括
皮疹和内分泌疾病等与免疫相关的不良事件 (irAEs) 预测,接受尼沃卢马布和伊皮利穆马布治疗的转移性细胞癌 (mRCC) 患者的生存率更好. 管理这些IRAE是改善结果的关键.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床研究 临床研究
背景情况:
- 与免疫相关的不良事件 (irAEs) 在转移性细胞癌 (mRCC) 的免疫瘤治疗期间很常见.
- 这些IRAE与mRCC患者改善的临床结果有关.
- 具体的IRE及其预后意义需要进一步调查.
研究的目的:
- 分析特定免疫相关不良事件 (irAEs) 与转移性细胞癌 (mRCC) 患者的预后之间的关联.
- 确定哪些iRAE与治疗nivolumab和ipilimumab的mRCC患者的无进展生存期 (PFS) 和整体生存期 (OS) 的改善有关.
主要方法:
- 从153名符合条件的转移性细胞癌 (mRCC) 患者进行了回顾性数据收集,这些患者接受了尼沃卢马布和伊皮利穆马布治疗.
- 进行了Cox比例危险分析,以评估irAEs对无进展生存 (PFS) 和整体生存 (OS) 的影响.
主要成果:
- 与内分泌疾病相关的irrAEs是改善PFS和OS的显著预后因素.
- 与疹相关的IRAE也被确定为显著的预后因素,特别是改善了OS.
- 观察到的最常见的irrAEs是内分泌系统疾病 (28.8%),皮疹 (18.3%),肺部疾病 (10.5%) 和肝功能障碍 (9.8%).
结论:
- 皮疹和内分泌疾病相关的irrAEs在接受nivolumab和ipilimumab的mRCC患者的生存结果的预测者.
- 有效管理这些特定的irAEs对于提高患者预后和治疗疗效至关重要.
更多相关视频
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
5.6K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.3K
相关概念视频
01:27Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
01:21Cancer Survival Analysis
455
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
455
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K